Shots: The P-III ELOQUENT-1 study involves assessing of Empliciti (elotuzumab)+ Revlimid (lenalidomide) and dexamethasone (ERd) vs Rd in transplant-ineligible patients with newly diagnosed, previously untreated MM The P-III ELOQUENT-1 study […]readmore
